Professional Bio
Dr. Messing received his MD degree from New York University in 1972, did his surgery training at NYU-Bellevue Hospital in New York 1972-1974, and his Urology Residency at Stanford University 1974-1978. After 2 years on the faculty at Tulane University, he completed a fellowship in Urologic Oncology at UCLA in 1982. He was on the faculty of the Division of Urology at the University of Wisconsin from 1982-1995, being Director of their Urologic Oncology Program for the last 10 years. He assumed his current
position at the University of Rochester School of Medicine and Dentistry in September 1995. Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the prostate, bladder, kidney, testicle, penis and other genitourinary organs, carries on extensive research in the basic biology of bladder and prostate cancers, and has been the principal investigator on numerous clinical studies for the detection, prevention and
treatment of genitourinary cancers.
Research Bio
Dr. Messing is an internationally renowned expert in all facets of urologic oncology, both as a clinician/surgeon, and as a clinical, translational and basic researcher.
His research contributions have ranged from enhancing our knowledge about the basic molecular biology and genetics of development and progression of cancers of the bladder, prostate and kidney, and bringing these studies to fruition for the detection, prevention and treatment of these diseases. He has also designed and conducted landmark phase III clinical trials for each of these cancers and has carried out the first
screening trial for bladder cancer in a general population. Important work has included defining the roles of epidermal growth factor (EGF) and its cell surface receptor in urothelial carcinogenesis and progression, investigating polyamine synthesis inhibition as a means to prevent bladder and prostate cancers, in large phase III clinical trials studying DFMO's ability to prevent bladder cancer's recurrence, the timing of androgen deprivation therapy (ADT) in treating regionally advanced completely resected prostate cancer, and the effectiveness of adjuvant alpha interferon for completely resected,
locally extensive, renal cell carcinoma. He has also contributed importantly to trials testing various forms of intravesical therapy for high risk, non-muscle invading bladder cancer, and the value of radiation therapy after prostatectomy for stage pT3 prostate cancer. He has demonstrated the feasibility of screening for bladder cancer (using hematuria reagent strips) and has worked on the development and testing of several molecular markers for the detection of bladder cancer.
Much of the above mentioned work continues, but currently he is also investigating gender disparities in bladder cancer's incidence and outcome. These efforts have ranged from investigations using large, national data bases, to molecular studies in cells and transgenic animal models. Additionally, he along with his basic science collaborators are investigating the preventative and therapeutic roles of nuclear transcription factors, vitamins and related molecules in prevention and treatment of prostate and bladder cancer. Furthermore, his clinical trial work
continues as the study coordinator (PI) of a large phase III clinical trial of immediate post TURBT intravesical instillation therapy for prevention of recurrence of low risk bladder cancer.
| Presidential Citation Award | American Urological Association | San Diego, CA |
2013 |
| 2010 Best of Posters Award | American Urological Association |
2010 - 2010 |
| Davey Award | James P. WIlmot Cancer Center | University of Rochester Medical Center |
2009 |
| CaP Cure Award | Best Clinical Research on Prostate Cancer |
1999 - 1999 |
| Fellow | American College of Surgeons |
1986 - Present |
| Sigma Xi | The Scientific Research Society |
1985 - Present |
| Junior Faculty Clinical Fellow | American Cancer Society |
1984 - 1986 |
| First Prize for Clinical Research and the Bill Smart Award for Best Clinical Paper (Interstitial Cystitis) | Northern California Urology Residents Seminar - Stanford, CA |
1977 - 1977 |
| Second Prize for Case Reports (Renal Arteriovenous Fistulas) | Northern California Urology Residents Seminar - Davis, CA |
1975 - 1975 |
| Alpha Omega Alpha | New York University - School of Medicine |
1972 - Present |
| The Samuel Soifer Memorial Award for Outstanding Work in Urology | New York University - School of Medicine |
1972 - 1972 |
| Phil Beta Kappa | University of Chicago |
1968 - Present |
2013 May
Yang D, Lin S, Ding X, Miyamoto H, Messing EM, Li L, Wang N, Chang C. "Higher expression of PPAR or its activation via an agonist TZD-rosiglitazone promotes bladder cancer cell migration and invasion". Urology. 2013; 81(5):1109. |
2013
Larre S, Catto J, Cookson M, Messing EM, Shariat S, Soloway M, Svatek R, Lotan Y, Zlotta A, Grossman HB. "Screening for bladder cancer: rationale, limitations, whom to target and perspectives". European Urology. 2013; 63(6): 1049-58. |
2013
Ghazi A, Scosyrev E, Patel H, Messing EM, Joseph JV. "Complications associated with extraperitoneal robot-assisted radical prostatectomy using the standardized Martin classification". Urology. 2013; 81(2): 324-31. |
2013
Weight CJ, Miller DC, Campbell SC, Derweesh IH, Lane BR, Messing EM. "The management of a clinical t1b renal tumor in the presence of a normal contralateral kidney". J Urol. 2013; 189(4): 1198-202. |
2013
Scosyrev E, Messing EM. "Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentaion: analysis of trends over time". Cancer. 2013; 119(5) 1113-4. |
